首页> 美国卫生研究院文献>Journal of Nanobiotechnology >Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes
【2h】

Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes

机译:基于纳米颗粒的胰岛素输送系统:用于1型糖尿病的下一代高效疗法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Diabetic cases have increased rapidly in recent years throughout the world. Currently, for type-1 diabetes mellitus (T1DM), multiple daily insulin (MDI) injections is the most popular treatment throughout the world. At this juncture, researchers are trying to develop different insulin delivery systems, especially through oral and pulmonary route using nanocarrier based delivery system. This next generation efficient therapy for T1DM may help to improve the quality of life of diabetic patients who routinely employ insulin by the subcutaneous route. In this paper, we have depicted various next generation nanocarrier based insulin delivery systems such as chitosan-insulin nanoparticles, PLGA-insulin nanoparticles, dextran-insulin nanoparticles, polyalkylcyanoacrylated-insulin nanoparticles and solid lipid-insulin nanoparticles. Modulation of these insulin nanocarriers may lead to successful oral or pulmonary insulin nanoformulations in future clinical settings. Therefore, applications and limitations of these nanoparticles in delivering insulin to the targeted site have been thoroughly discussed.
机译:近年来,糖尿病病例在世界范围内迅速增加。目前,对于1型糖尿病(T1DM),每天多次注射胰岛素(MDI)是世界上最受欢迎的治疗方法。目前,研究人员正在尝试开发不同的胰岛素输送系统,尤其是通过使用基于纳米载体的输送系统通过口服和肺部途径。这种新一代的T1DM有效疗法可能有助于改善通常通过皮下途径使用胰岛素的糖尿病患者的生活质量。在本文中,我们描述了各种基于下一代纳米载体的胰岛素递送系统,例如壳聚糖-胰岛素纳米颗粒,PLGA-胰岛素纳米颗粒,葡聚糖-胰岛素纳米颗粒,聚烷基氰基丙烯酸酯化胰岛素纳米颗粒和固体脂质-胰岛素纳米颗粒。这些胰岛素纳米载体的调节可能会导致未来临床环境中成功的口服或肺部胰岛素纳米制剂。因此,已经充分讨论了这些纳米颗粒在将胰岛素递送至靶位点中的应用和局限性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号